Objective:

To build a model of infliximab use in a population of patients with Inflammatory Bowel Disease to determine the cost effectiveness of Therapeutic Drug Monitoring as well as to determine the optimal interval for repeat monitoring.

Methods Used:

We were unable to perform an analysis based on the available data.

Results: None

Conclusions: N/A